RxDoctor Payments Data

James Steckelberg, MD

Family Medicine · Syracuse, NENPI 1962419713

Payments from drug & device makers

$942in general payments, 2019–2025

Across 58 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$128
  • Lundbeck LLC$94
  • Lilly USA, LLC$74
  • Amgen$70
  • Sunovion Pharmaceuticals Inc.$68
  • AbbVie$60
  • plus $448 from 15 others

What the payments were for

  • Food & beverage$90396%
  • Education$394%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$942 in reported general payments places this provider in the 60th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$8,543
Medicare patients
46
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban299$216,866
TrulicityDulaglutide106$115,708
FarxigaDapagliflozin Propanediol148$102,638
JardianceEmpagliflozin114$94,732
MounjaroTirzepatide78$86,567
XareltoRivaroxaban125$86,476
MyrbetriqMirabegron141$56,476
OzempicSemaglutide38$35,240
Tresiba Flextouch U-100Insulin Degludec48$31,726
EntrestoSacubitril/Valsartan18$20,002
Tresiba Flextouch U-200Insulin Degludec26$19,742
Breo ElliptaFluticasone/Vilanterol40$19,712
KerendiaFinerenone21$17,536
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$16,659
ArexvyRsvpref3 Antigen/As01e/Pf53$16,553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$38$227,958335 claims
Lilly USA, LLCTrulicity, Mounjaro$74$202,275184 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$59$116,482185 claims
Astellas Pharma US IncMyrbetriq$18$56,476141 claims
Novo NordiskOzempic$33$35,24038 claims
NovartisEntresto$128$20,00218 claims
BayerKerendia$54$17,53621 claims
AbbVieLinzess$60$15,43629 claims
Otsuka America Pharmaceutical, Inc.Rexulti$32$9,98117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Syracuse

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →